tiprankstipranks
Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719)
:0719
Hong Kong Market
0719
Shandong Xinhua Pharmaceutical Company Limited Class H
RESEARCH TOOLSreports

Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Financial Statements

Compare
2 Followers

Shandong Xinhua Pharmaceutical Company Limited Class H Financial Overview

Shandong Xinhua Pharmaceutical Company Limited Class H's market cap is currently HK$8.97B. The company's EPS TTM is HK$0.716; its P/E ratio is 7.98; and it has a dividend yield of 5.27%. Shandong Xinhua Pharmaceutical Company Limited Class H is scheduled to report earnings on March 26, 2025, and the estimated EPS forecast is HK$0.17. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Dec 21Dec 20Dec 19
Income Statement
Total Revenue¥ 8.10B¥ 7.50B¥ 6.56B¥ 6.01B¥ 5.61B
Gross Profit¥ 2.32B¥ 2.04B¥ 1.77B¥ 1.81B¥ 1.87B
Operating Income¥ 534.58M¥ 476.71M¥ 425.59M¥ 422.49M¥ 387.44M
EBITDA¥ 1.09B¥ 1.01B¥ 840.20M¥ 856.79M¥ 781.34M
Net Income¥ 496.51M¥ 411.06M¥ 348.55M¥ 324.86M¥ 299.97M
Balance Sheet
Cash & Short-Term Investments¥ 918.33M¥ 1.16B¥ 744.66M¥ 855.77M¥ 690.47M
Total Assets¥ 8.29B¥ 8.27B¥ 7.33B¥ 7.09B¥ 6.44B
Total Debt¥ 1.08B¥ 1.38B¥ 1.04B¥ 1.09B¥ 1.48B
Net Debt¥ 166.60M¥ 225.11M¥ 299.09M¥ 231.77M¥ 789.16M
Total Liabilities¥ 3.51B¥ 3.92B¥ 3.68B¥ 3.70B¥ 3.33B
Stockholders' Equity¥ 4.55B¥ 4.13B¥ 3.47B¥ 3.22B¥ 2.97B
Cash Flow
Free Cash Flow-¥ 513.48M¥ 9.89M¥ 140.00M-
Operating Cash Flow¥ 265.28M¥ 758.24M¥ 259.12M¥ 420.19M¥ 348.27M
Investing Cash Flow-----
Financing Cash Flow¥ -196.11M--¥ 35.04M-
Currency in CNY

Shandong Xinhua Pharmaceutical Company Limited Class H Earnings and Revenue History

Shandong Xinhua Pharmaceutical Company Limited Class H Debt to Assets

Shandong Xinhua Pharmaceutical Company Limited Class H Cash Flow

Shandong Xinhua Pharmaceutical Company Limited Class H Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis